Who makes fIPV (0.1 mL) ID?

fIPV (0.1 mL) ID is developed by Centers for Disease Control and Prevention.

What development phase is fIPV (0.1 mL) ID in?

fIPV (0.1 mL) ID is FDA-approved (marketed).

What are the side effects of fIPV (0.1 mL) ID?

Common side effects include Local injection site reactions (pain, erythema, induration), Fever, Myalgia.

Last reviewed 2026-04-22 · How we verify

fIPV (0.1 mL) ID

Centers for Disease Control and Prevention · FDA-approved active Biologic

fIPV is an inactivated polio vaccine that stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3.

fIPV is an inactivated polio vaccine that stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3. Used for Poliomyelitis prevention in outbreak response and immunization campaigns, Polio vaccination in resource-limited settings using fractional dosing.

At a glance

Generic name	fIPV (0.1 mL) ID
Sponsor	Centers for Disease Control and Prevention
Drug class	vaccine
Target	poliovirus types 1, 2, and 3 antigens
Modality	Biologic
Therapeutic area	Immunology
Phase	FDA-approved

Mechanism of action

fIPV (fractional inactivated polio vaccine) contains chemically inactivated poliovirus antigens that trigger humoral and cellular immune responses without causing disease. The vaccine is administered intradermally in a reduced dose (0.1 mL) compared to standard intramuscular IPV, providing immunogenicity while conserving vaccine supply. This formulation is used in outbreak response and resource-limited settings to extend vaccine availability.

Approved indications

Poliomyelitis prevention in outbreak response and immunization campaigns
Polio vaccination in resource-limited settings using fractional dosing

Common side effects

Local injection site reactions (pain, erythema, induration)
Fever
Myalgia

Key clinical trials

Immunogenicity of Intramuscular and Intradermal IPV (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

fIPV (0.1 mL) ID CI brief — competitive landscape report
fIPV (0.1 mL) ID updates RSS · CI watch RSS
Centers for Disease Control and Prevention portfolio CI